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ABSTRACT 
 
The initiation of new bone formation within the porous spaces of 
hydroxyapatite (HA) implants involves the expression of osteogenic 
markers belonging to the TGF-β superfamily. To study the genetic 
expression of these osteogenic markers in relation to the type of HA 
implant used and implantation period, five different types of porous HA 
biomaterials were implanted in the rectus abdominis muscles of adult 
baboons Papio ursinus, and were harvested at two, three and 12 months. 
The total RNA of all harvested samples was extracted and analysed using 
the Northern blot technique. The results showed that Collagen type IV, 
GDF-10 and BMP-7 were expressed at the early time points at relatively 
high levels, and their expression levels were significantly reduced at 12 
months. The expression of these makers was not affected by the type of 
porous HA implant used. The histological sections of these specimens at 
two and three months showed vascularised connective tissue within the 
porous spaces of the implants with no bone formation. However, at 12 
months there were substantial amounts of bone formed in all the studied 
implants. The down-regulation of the expressed osteogenic markers at 12 
months correlates to the amount of bone formed, suggesting some 
negative feedback mechanism which may be acting via inhibitory Smads 
proteins in relation to the amount of bone formed. Neither TGF-β1 nor 
BMP-3 messages were detected in any of the studied samples, It is 
 v
possible that these bone markers are not expressed locally within the 
vicinity of the porous HA implants but are adsorbed to the HA implants from 
the circulatory system. 
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1 INTRODUCTION 
 
A living bone has an intrinsic capacity to regenerate and repair itself thus 
making most treatment easy. Nonetheless, there are numerous bone 
defects that require the use of autografts, and in circumstances where 
there is not enough bone available for autograft reconstitution, allografts 
are used. The use of bone grafts brings complications to the patient such 
as donor site morbidity, graft strength, risks of viral transmission as well as 
antigenic incompatibility (Yoshikawa et al., 1996; White and Shors, 1986).  
Owing to these conditions, alternatives have been developed such as the 
use of osteoconductive biomaterials as a substitute to bone grafts. Studies 
(Jarcho, 1986; Shors et al., 1989; Ripamonti, 1991; 1996; Ripamonti & 
Reddi, 1994; Whang et al., 1998; Saito et al., 2001) have been performed 
on several materials investigating their compatibility and their ability to act 
as bone graft replacement devices. These materials range from natural or 
man-made, comprising of whole or part of living structures or biomedical 
devices.  
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1.1 Bone Formation by Induction 
 
 
The quest to find a biomaterial that can be used as a substitute for bone 
graft was pioneered over a century ago by Senn (1889), who demonstrated 
that decalcified bone matrix could be used in treatment of osteomyelitis. 
Lacroix (1945) postulated that the bone matrix possessed an osteogenic 
inducer ‘osteogenin’ which was responsible for generating new bone in 
recipients when implanted intramuscularly or subcutaneously. A major 
breakthrough was made by Urist (1965), who demonstrated that 
demineralised bone matrix (DBM) was capable of forming new bone when 
implanted heterotopically in rodents. Urist described this phenomenon as 
bone formation by induction (Urist, 1965). 
 
Reddi and Huggins (1972) elicited more information about bone formation 
by induction when they implanted the DBM in subcutaneous sites of rats 
and characterised the sequence of events that developed upon 
implantation. They noted that bone formation resulted from the following 
events; chemo-attraction of the mesenchymal cells to the implanted DBM, 
mesenchymal  cells differentiation, chondrogenesis, vascular invasion, 
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chondrolysis, osteoblast differentiation, bone matrix synthesis and 
mineralisation. 
 
The observation that demineralised bone matrix (DBM) was capable of 
inducing new bone formation in extraskeletal sites using the rodent 
bioassay (Urist, 1965; Reddi & Huggins 1972), suggested that there were 
bone forming proteins within the DBM.  This led to attempts of solubilising 
the proteins of the DBM.  However, the organic and inorganic components 
of the DBM were tightly bound to each other, leading to difficulties in 
dissociating the two components. This biochemical problem was unlocked 
by the use of dissociative extractants such as 4M guanidium hydrochloride 
which successfully extracted and solubilised the bone–inductive proteins 
from the bone matrix. Once separated, neither the solubilised proteins in 
the extract nor the remaining insoluble collagenous bone matrix (ICBM) 
were osteoinductive in the heterotopic bioassay in rodents (Sampath & 
Reddi, 1981). However, reconstitution of the solubilised protein extract with 
the ICBM restored the biological activity (Sampath & Reddi, 1981).  
 
More work conducted on the ICBM and the solubilised protein extracts 
(Ripamonti, 1991), showed that the osteogenic activity in rodents’ 
heterotopic bioassays could only be achieved by reconstituting mammalian 
solubilised protein extracts with rodent ICBM. Also, osteogenic activity in 
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baboons could only be achieved by reconstitution of mammalian solubilised 
protein extractants with baboon ICBM (Ripamonti, 1991).  This showed that 
while the osteogenic proteins are highly conserved between species, the 
ICBM retains species-specific insoluble immunological components which 
can inhibit the heterologous bone-induction cascade (Sampath & Reddi, 
1983). However, the solubilised protein extracts can be used in any 
mammalian species, suggesting homology between bone-inductive 
proteins from different mammalian bone extracellular matrix. 
 
As it was shown that ICBM without the solubilised proteins could not initiate 
bone formation (Sampath & Reddi, 1981), the study of the solubilised 
proteins became imperative.  These solubilised proteins were extracted 
from the DBM, characterised, isolated, purified and identified as bone 
morphogenetic proteins (BMPs) (Wang et al., 1988; Luyten et al., 1989). It 
was also established that these BMPs belong to the transforming growth 
factor beta (TGF-β) superfamily of proteins. 
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1.2 The Transforming Growth Factor beta  (TGF-β)   
Superfamily 
 
The TGF-β superfamily consists of a large group of morphogens which play 
pivotal roles in tissue morphogenesis and differentiation. Members of this 
superfamily participate in setting up the basic body plan during 
embryogenesis in different groups of animals from insects and amphibians 
to mammals. They control formation of the neural tube, limb, cartilage, 
bone and sexual organs. They play a major role in the regulation of 
cartilage and bone during embryonic development and in post-natal life 
(Reddi, 1994; 1997; 1998; Urist, 1997).  
 
Members of the TGF-β superfamily includes five isoforms of TGF-β (TGF-
β1 to TGF-β5) (Sporn & Roberts,1990); bone morphogenetic proteins 
(BMPs); (Wozney et al., 1988) activins; inhibins (Schwall et al., 1988), the 
60A (Wharton et al., 1991); decapentaplegic gene product of Drosophila 
melanogaster (Ferguson & Anderson, 1992), the Vg-1 gene product of 
Xenopus laevis (Weeks & Melton, 1987); Vg-1-related murine analogue of 
murine Vgr-1 (Lyons et al., 1989), the growth and differentiation factors 
(GDFs) (Lee, 1991) and the cartilage derived morphogenetic proteins 
(CDMPs) (Chang et al., 1994). 
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The critical mediators of the TGF-β signal transduction pathways are 
defined as Smad proteins. These proteins carry the signal from the 
membrane bound type I and type II receptors and transduce it to the 
nucleus (Massagué, 1996). Once in the nucleus Smad proteins interact 
with other DNA-binding proteins to regulate transcription of specific target 
genes (Massagué, 1996). Subsequent studies divided Smad proteins into 
three groups: receptor-activated Smads (R-Smads); inhibitory Smads (I-
Smads), and the co-activator Smad 4, which binds to activated R-Smads 
(Reddi, 1998).  
 
At present eight different Smads have been identified, Smad 1, 5, and 8 
are substrates of BMP receptors. Smads 2 and 3 are substrates of TGF-β 
and activin receptors. Phosphorylation of Smads 1, 5, or 8 activates their 
interaction with common functional partner Smad 4, and forms a 
heteromeric complex with it (Massagué, 1996).  Smad 4 assists 
translocation of the receptor–activated Smads into the nucleus where this 
complex activates BMP-responsive genes.  There are two inhibitory 
Smads, viz. 6 and 7. These inhibitory Smads reside in the nucleus and act 
as a relay to turn-off the type I receptor kinase mediated phosphorylation of 
Smads 1, 5, and 8 (Massagué, 1996; Reddi, 1998; 2001). 
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1.2.1  Bone Morphogenetic Proteins (BMPs) 
 
BMPs were the first members of the TGF-β superfamily to be identified as 
osteoinductive. They were able to induce bone formation when combined 
with ICBM and implanted intramuscularly or subcutaneously (Reddi, 1992). 
Approximately 30 BMP isoforms have been identified, sequenced and 
cloned to date. Of these isolated gene products, BMP-1 is the only one that 
is not a member of TGF-β superfamily and does not possess any 
osteogenic activity. Instead BMP-1 is a cleaving procollagen protease, a 
collagen precursor (Kessler et al., 1996).  
 
One of the first BMPs to be isolated and purified was called osteogenin 
(Wozney et al., 1988). As more studies were done on BMPs, it was 
observed that the amino acid sequence of the tryptic peptides of 
osteogenin had a primary structure which was identical to the amino acid 
sequence deduced from the cDNA clones of human BMP-3 (Wozney et al., 
1988; Luyten et al., 1989) implying that osteogenin and BMP-3 are one and 
the same protein. Later native BMP-3 (osteogenin) was isolated and 
purified to homogeneity from baboon bone matrix (Ripamonti et al., 1992c).  
 
Advances in molecular techniques have resulted in the identification of 
several other gene-related products of BMP family which have been cloned 
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and expressed (Özkaynak et al., 1990; 1992; Celeste et al., 1990). There 
was also a construction of a synthetic consensus gene on basis of 
structural information from Drosophila dpp, Xenopus Vg-1 and amino acid 
sequences of native bovine osteogenic protein (Sampath et al., 1990). This 
resulted in identification of a novel human gene, related to murine gene 
Vgr-1, encoding a member of the BMP family, the osteogenic protein-1 
(OP-1) (Özkaynak et al., 1990). It is now clear that BMP-7, identified 
subsequently together with BMP-5 and BMP-6 (Celeste et al., 1990) is 
identical to OP-1.  
 
To activate BMP response genes, the signal is sent via specific Smads 
proteins to the cell nucleus. When reaching the nucleus the signaling 
cascade activates expression of the response genes leading to the 
synthesis of macromolecules involved in cartilage and bone formation by 
inducing the mesenchymal cells to become chondroblasts or osteoblasts 
(Massagué, 1996). Noggin and chordin were identified as BMP antagonists 
as they have some affinity to BMP like the BMP-receptors (Zimmerman et 
al., 1996).  
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1.2.2 TGF-β  Isoforms 
 
TGF-β proteins are 25 kDa proteins comprising two 12.5 kDa subunits held 
together by disulphide linkage (Assoian et al., 1983). The TGF-β family 
comprises five closely related isoforms called TGF-β1 to –5 (Sporn & 
Roberts, 1990).  
 
As with BMPs, the carboxy terminal domain of the TGF-βs is highly 
conserved between species (Roberts et al., 1991). TGF-β5 was identified 
in Xenopus laevis, while TGF-β4 was also discovered in human 
endometrium and described as an endometrial bleeding associated factor 
(EBAF) (Kothapalli et al., 1997; Tabibzadeh et al., 1997). TGF-β1, TGF-β2 
and TGF-β3 were found to be mammalian (Wataya-Kaneda et al., 1994). 
TGF-β1 is identical in man, monkey, cow and chicken. TGF-β2 is 71%   
homologous to TGF-β1, while the other TGF-βs share homology in the 
range of 64% to 83% with TGF-β1 (Roberts et al., 1991). The mature 
region of TGF-β3 has an approximately 80% identity to the mature regions 
of TGF-β1 and TGF-β2. The precursor regions of the first three isoforms 
share 27% sequence identity (ten Djike et al., 1988; Derynck et al., 1988).   
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The fact that TGF-βs are not osteoinductive in rodents does not exclude 
their requirement and interaction with other bone morphogens during the 
complex and co-coordinated molecular events that control cell proliferation 
and differentiation culminating in the organogenesis of bone complete with 
marrow (Centrella et al., 1994; Reddi, 1994). This is supported by the fact 
that TGF-β1 and TGF-β2 are found in the extracellular bone matrix 
together with BMPs and other growth factors. However, the relationship 
between BMPs and other TGF-βs found in the extracellular bone matrix is 
poorly understood. Although TGF-β1 and TGF-β2 share a limited homology 
with BMP proteins, BMP4 and BMP-7 do not have overlapping receptor 
binding specificity with TGF-βs (ten Dijke et al., 1994).  
 
TGF-β family members play a role in repair and regeneration of tissues 
during post-fetal life (Sporn & Roberts, 1990; Derynck et al., 1994; 
Kingsley; 1994). While during embryogenesis the TGF-β proteins play a 
critical role in the migration, proliferation and differentiation of a variety of 
cells (Heine et al., 1987; Pelton et al., 1990). 
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1.2.3 Growth Differentiation Factors (GDFs) 
 
Using procedure adapted from that used for the isolation of BMPs from the 
bone matrix (Wang et al., 1988; Luyten et al., 1989), other morphogenetic 
proteins were identified in cartilage matrix. These are the cartilage-derived 
morphogenetic proteins (CDMPs) also known as growth differentiation 
factors (GDFs). These proteins belong to the TGF-β superfamily and are 
closely related to BMP-5, -6 and –7 (Chang et al., 1994). In contrast to the 
other members of the BMP family, expression of CDMP-1 and –2 is 
predominantly in cartilagenous tissues and particularly in condensing 
mesenchyme of developing limbs (Chang et al., 1994). The mouse 
equivalent of CDMP-1 called GDF-5 is linked to a mouse disorder 
characterised by a distinct shortening of the limbs without other tissue 
abnormalities (Storm et al., 1994). 
 
GDF-10 was identified as a gene product closely related to BMP-3 and the 
two proteins are classified under their own subgroup in the TGF-β 
superfamily.  The mature carboxy-terminal domain of GDF-10 and BMP-3 
have 83% amino acid sequence identity and the pro-regions of these two 
proteins are also homologous having approximately 30% amino acid 
sequence identity (Cunningham et al., 1995). 
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GDF-10 is also present in both neonatal and adult bone samples, with 
higher levels being detected in calvaria than in long bones. These findings 
indicate that GDF-10 may play a role in regulating cell differentiation 
events, including those involved in skeletal morphogenesis.  GDF-10 was 
mapped to the proximal region of mouse chromosome 14 close to a region 
known to contain a spontaneous recessive mutation that is associated with 
craniofacial defects (Cunningham et al., 1995). 
 
 
 13
1.3 Delivery Vehicles of Bone Forming Proteins. 
 
In order to induce new bone formation, it is necessary to have both an 
osteoinductive protein and delivery vehicle. The proteins of the TGF-β 
superfamily are osteoinductive. However, there is a need to search for a 
biomaterial that could act as a suitable delivery vehicle for these 
osteoinductive proteins and be able to act as a scaffold supporting new 
bone that is being formed, while maintaining a space or volume in which 
bone formation can occur.   
 
There are many biomaterials that could be used as delivery vehicles for 
bone forming proteins but not all meet the ideal. The ideal osteogenic 
biomaterial should be biocompatible i.e. not cytotoxic or able to elicit 
excessive inflammatory responses which interfere with bone induction 
(Shors et al., 1989). To fulfill its function the biomaterial must be cell-
compatible enabling it to support cell proliferation and provide a suitable 
attachment substratum. Also, it should be capable of directly influencing 
cellular differentiation and expression of the osteogenic phenotype 
(Anselme, 2000). Moreover, biomaterials should act by binding to BMPs 
and presenting the proteins to cell receptors directly (Reddi & Cunningham, 
1993).  The slow release of BMPs is critical as it provides physiological 
concentration of BMPs in the vicinity of the implant for a prolonged time. 
 14
The released BMPs are capable of attracting target cells by chemotaxis to 
a desired site for bone induction (Cunningham et al., 1992). 
 
Insoluble collagenous bone matrix (ICBM) has been commonly used as a 
delivery system for bone forming proteins. A clinical trial has been  made 
on patients with tibial nonunions, treating patients by inserting an 
intramedullary rod and recombinant human (rh)-BMP-7 delivered by the 
insoluble collagenous bone matrix, a xenogeneic bovine matrix packed 
along the rod (Friedlander et al., 2001). Results showed that rh-BMP-7 
treated nonunions healed as well as nonunions treated by autografts. 
However, the patients treated with rhBMP-7 did not suffer from donor site 
pain as compared to patients treated with autografts (Friedlander et al., 
2001). In Baboons ICBM combined with TGF-β1 and BMP-7 showed that 
the two morphogens synergised to bring about rapid bone formation 
heterotopically (Ripamonti et al., 1997). 
 
The delivery systems that have also proved to be osteoconductive are 
polymer matrices which are made out of α-hydroxy acid polymers, poly 
(lactide) (PL), poly (gly-colide) (PG) and their copolymers (Whang et al., 
1998). In one study (Saito et al., 2001) poly-D, L-lactic acid-polyethylene 
glycol block copolymers (PLA-PEG) were used as delivery systems for 
BMP-2. This study showed that heterotopic implantation of these polymers 
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carrying BMP-2 in mice would show new bone formation having 
hematopoietic marrow and osseous trabecular after three weeks of 
implantation. However there was no bone formed in polymers which had no 
BMP-2 (Saito et al., 2001). Another study showed that PLA-PEG blend 
microparticles can serve as delivery vehicles for controlled release of TGF-
β 1 also initiating bone formation (Lu et al., 2001). 
 
Calcium phosphate bioceramics have been studied and used as delivery 
vehicle for BMPs, hydroxyapatite (HA) and tricalcium phosphate (TCP) are 
one of these calcium phosphate ceramics. Hydroxyapatite is a natural 
component of bone tissue; it is non-resorbable and thus suitable for long 
term restorative clinical procedures (Jarcho, 1986). While TCP is 
chemically similar to HA it is partially resorbable and could be used in non-
pathological sites where resorbability of the implant would be needed. It is 
worth noting that a highly resorbable implant could be resorbed before 
complete new bone formation has occurred (Shors et al., 1989), thus failing 
to support the new forming bone. 
 
A significant breakthrough was made in the search for osteoconductive 
delivery vehicles, in a study involving porous hydroxyapatite implants which 
were implanted heterotopically in rabbits, dogs and baboons (Ripamonti, 
1996). After 90 days of implantation it was found that there was minimal 
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amount of bone that was formed in implants harvested from rabbits and 
dogs and a substantial amount of bone formed in baboons. This 
experiment showed that in primates, porous hydroxyapatite implants could 
induce bone formation without any exogenous addition of osteogenic 
proteins, i.e. without being used as a delivery system for osteogenic 
proteins (Ripamonti, 1996). This means that the porous hydroxyapatite 
implants can intrinsically induce bone formation. With these interesting 
findings it was clear that more studies should be conducted, in order to 
understand the mechanisms behind not just osteoconductive properties but 
also osteoinductive properties of porous hydroxyapatite implants. 
 
1.3.1 Osteoinductive Porous Hydroxyapatite Implants 
 
1.3.1.1 Manufacturing of Hydroxyapatite Implants 
Hydroxyapatite [Ca10(PO4)6(OH)2] forms the main mineral component of the 
bone matrix. It is deposited as spindle shaped crystals along the collagen 
fibres during embryogenesis (Holmes & Hagler, 1988).  Hydroxyapatite 
implants have been made in such a way that their infrastructure mimics 
that of the natural bone. Since hydroxyapatite is naturally found in bones it 
is biocompatible and would not evoke inflammatory response from the 
recipient thus making it a good delivery vehicle  
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Some of the hydroxyapatite implants used presently in pre-clinical and 
clinical studies are derived from corals, the marine invertebrates which 
secrete calcium carbonate exoskeletons. Porites and Goniopora mainly 
grow in groups of interconnected members and are the two coral species 
that are commonly used because their porous structure is similar to the 
architecture of bone (White & Shors, 1986). The similarity of these corals’ 
architecture to bone, led to development of a hydrothermal phosphate 
exchange technique used to convert the calcium carbonate exoskeleton of 
corals into calcium phosphate (hydroxyapatite) (Roy & Linnehan, 1974).   
 
The two coral species normally used in manufacturing hydroxyapatite are 
very similar architecturally, but their pore sizes differ. Porites species have 
an average pore diameter of 200 µm and hydroxyapatite implants derived 
from this coral use a trade name of Interpore 200 (Interpore International, 
Irvine, CA). Goniopora species have an average pore diameter of 600 µm 
and hydroxyapatite implants manufactured from these corals use a trade 
name of Interpore 500 (Interpore International, Irvine, CA) (Holmes et 
al.,1986). 
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1.3.1.2  Hydroxyapatite Implants Intrinsically Inducing New Bone 
 As already mentioned, it was found that intramuscular implantation of 
certain porous hydroxyapatite in baboons resulted in new bone formation 
within the porous spaces and in direct apposition to the hydroxyapatite 
(Ripamonti, 1991).  What was striking about these results is that there was 
no exogenous application of BMPs on the implant. From a therapeutic 
perspective, an implant is required for local delivery of rhBMPs to evoke a 
desired osteogenic response, because it is the composite of a biomaterial 
carrier together with rhBMPs that triggers the bone induction cascade 
(Ripamonti & Reddi, 1994). These results (Ripamonti, 1991) indicate that 
porous hydroxyapatite biomaterials induced bone formation when 
implanted heterotopically in recipient animals, without any addition of 
exogenously applied BMPs was surprising. In addition the same results 
showed that porous hydroxyapatite could intrinsically induce bone 
formation at least in primate species.  
 
 
1.3.1.3 Adsorption of Osteogenic Proteins onto the Hydroxyapatite 
Implants  
It has been speculated that the intrinsic osteoinductive properties seen in 
porous hydroxyapatite, is a result of circulating and/or released 
extracellular matrix morphogens binding to hydroxyapatite until the 
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morphogens reach a certain concentration threshold that then triggers new 
bone morphogenesis as a secondary response (Ripamonti et al.,1999).  
Experiments have shown that BMPs have high affinity to hydroxyapatite, 
explaining why endogenously produced BMPs could be attracted to 
hydroxyapatite and bind to it (Ripamonti & Duneas, 1998; Ripamonti, 
1996). This is supported by the in vitro binding of rhBMP-4 to porous 
hydroxyapatite, and by rapid generation of bone in porous hydroxyapatites 
pretreated with BMPs in heterotopic sites of rodents (Ripamonti et al., 
1992b) and orthotopic and heterotopic sites in baboons (Ripamonti et al., 
1992c; 1993).  
 
Sequential time studies on porous hydroxyapatite harvested at one month 
(Ripamonti et al., 1992b), two months (Ripamonti et al., 1993), three 
months (Ripamonti, 1991; 1996), six months and nine months (Ripamonti, 
1991) showed that bone differentiation in porous hydroxyapatite occurs by 
day 60 after implantation. This observation, combined with lack of bone 
differentiation in specimen harvested on day 30 after implantation, 
suggests that the initiation of bone formation may depend on a critical 
concentration of endogenously-produced morphogens adsorbed onto the 
hydroxyapatite.   
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1.3.1.4 Hydroxyapatite Implants and Animal Models 
When studying osteoinductivity of porous hydroxyapatite, another critical 
parameter to be considered is the type of animal model used, as 
demonstrated in several studies (Goshima et al., 1991; Miller et al.1991; 
Ripamonti, 1992a; 1996). A study was conducted   in which porous 
hydroxyapatite substrata were implanted in dogs and rabbits, this resulted 
in minimal bone formation (Ripamonti, 1996). In rats, subcutaneous or 
intramuscular implantation of porous hydroxyapatite does not initiate bone 
formation (Goshima et al., 1991; Ripamonti et al., 1989). Previously 
published experiments in rabbits have also shown lack of bone formation 
within the porous spaces of hydroxyapatite when implanted intramuscularly 
(Miller et al., 1991). However, bone differentiation occurred when sintered 
or coral hydroxyapatites were complexed with BMPs (Ripamonti et al., 
1992a; Takaoka et al., 1988). 
 
Compared to dogs and rodents implantation of porous hydroxyapatite in 
baboons (Papio ursinus) intrinsically induced bone formation (Ripamonti, 
1991; 1996; Ripamonti et al., 1992a, 1993).  The bone physiology of 
baboons is similar to those of humans, making baboons more suitable 
models for pre-clinical studies in bone formation (Schnitzler, et al., 1993). 
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1.3.1.5  Pore Size and Geometry of Hydroxyapatite Implants 
The physical parameters of porous hydroxyapatite play a significant role in 
bone induction. It has been shown that interconnectivity and pore size 
affect tissue infiltration in the implant. Lack of interconnectivity may lead to 
incomplete vascularisation of the bone tissue inside the implant, promoting 
infection and failure of the implant (Holmes et al., 1987). It has also been 
demonstrated that pore sizes less than 10 µm result in no tissue infiltration, 
pore sizes between 15 µm – 50 µm result in fibrovascular invasion, pore 
sizes between 50 µm – 150 µm result in osteoid formation, and pore sizes 
greater than 150 µm result in mineralised bone ingrowth (Chiroff et al., 
1975).  
 
Recently, studies conducted on porous hydroxyapatite physical parameters 
showed that the geometry and pore size of the implants are of great 
importance.  One of the first studies on importance of hydroxyapatite 
geometry in new bone formation was conducted on Long-Evans rats. In 
this study, nonresorbable porous hydroxyapatite in granular and disc 
configurations of 200 and 500 µm pore sizes were pretreated with bovine 
osteogenin, and no osteogenin in controls (Ripamonti et al., 1992a).  The 
biomaterials were implanted subcutaneously and harvested after seven, 11 
and 21 days. Bone differentiation was observed solely in osteogenin-
treated discs as early as seven days after implantation. The osteogenin-
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treated discs also showed high alkaline-phosphatase activity, a marker 
enzyme for osteoprogenitor and osteoblastic cells compared to granular 
implants. The control implants with no osteogenin did not induce bone 
differentiation. The most striking discovery in this study was that bone did 
not form in any of the osteogenin-treated granular hydroxyapatite implants 
in all pore sizes (Ripamonti et al., 1992a), showing the importance of 
geometry in hydroxyapatite implants. 
 
Another study (van Eeden & Ripamonti, 1994) was conducted comparing 
two distinct geometric configurations of porous hydroxyapatite implants 
having two different pore sizes.  The substrata were blocks of 
hydroxyapatite in rod configuration of 200 µm and 500 µm pore size and 
granular hydroxyapatite implants (van Eeden & Ripamonti, 1994). The 
biomaterials were implanted intramuscularly in eight subadult male 
baboons. Specimens were harvested after 60 and 90 days and subjected 
to histological and histomorphometric analyses. Bone was only found in 
blocks of hydroxyapatite in rod configuration at both observation periods. 
The lack of bone formation in the granular hydroxyapatite indicates the 
critical role of geometry of the substratum in bone differentiation (van 
Eeden & Ripamonti, 1994). The convex geometry of granular 
hydroxyapatite implants did not induce bone formation, while concavities 
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found in the porous spaces of blocks of hydroxyapatite encourages rapid 
vascularisation and mesenchymal cell invasion.  
 
In another experiment (Magan & Ripamonti, 1996) hydroxyapatite discs 
were prepared by cutting the implant either longitudinally or transversally 
according to the corallite geometry. Implants with different configurations 
were implanted in calvarial defects of subadult baboons and harvested on 
day 90 after surgery. Histomorphometric analysis on undecalcified and 
decalcified sections showed greater amounts of bone formed in porous 
hydroxyapatite cut in the longitudinal plane when compared with 
hydroxyapatites cut in transverse plane. These results indicated that the 
porous configuration of longitudinally prepared discs might be promoting 
superior osteoconductivity, possibly by enabling faster fibrovascular 
ingrowth (Magan & Ripamonti, 1996) since angiogenesis is a prerequisite 
for osteogenesis (Trueta, 1963).  
 
Monolithic discs of sintered hydroxyapatite, fabricated with concavities of 
800 µm and 1600 µm diameter in both planar surfaces were implanted in 
rectus abdominis muscles of the baboon (Papio ursinus). Histological 
results on days thirty and ninety revealed bone formation exclusively within 
the concavities of hydroxyapatite substrata. Subsequently, porous 
hydroxyapatites were fabricated with porous spaces formed by the 
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coalescence of repetitive sequence of concavities (Ripamonti et al., 1999).  
These were sintered in rod and disc configurations for implantation in 
intramuscular and calvarial sites, respectively. Bone formed in concavities 
of the substratum 30 days after implantation in the rectus abdominis 
muscles and after 90 days of implantation there was bone morphogenesis 
associated with bone marrow.  Calvarial specimen showed substantial 
bone formation, culminating in complete penetration of bone within the 
porous spaces. On day 30, immunolocalisation of BMP family members 
(BMP-3 and BMP-7) in cellular material at the hydroxyapatite interface 
suggested that the sintered substratum acts as a solid-state matrix for 
adsorption of endogenously produced BMPs. These experiments 
demonstrate intrinsic osteoinductivity of monolithic and porous 
hydroxyapatites. Furthermore it indicates that the geometry of the 
substratum profoundly regulates the expression of the osteogenic 
phenotype (Ripamonti et al., 1999).   
 
1.3.1.6  Chemical Composition of Hydroxyapatite Implants 
The chemical composition of hydroxyapatites also plays a major role as it 
greatly affects its biodegradability (Shors et al., 1989).  Biodegradability is a 
desirable attribute because if biodegradable and resorbable the implant 
would be ideal for segmental defect repair, as the implant would decrease 
the effects of residual carrier on the biomechanical properties of repair. The 
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main challenge is that rapid biodegradation does not give the implant 
enough time to induce bone formation and support the newly formed bone. 
Calcium carbonate implants biodegrade rapidly thus segmental defects do 
not close when treated with these implants (Shors et al.1989).  It is 
important that the rate of biodegradation should not exceed the rate of 
bone morphogenesis. Also the reduction of implant strength should 
correspond with the increase in new bone strength (Klein et al., 1990). 
 
As already mentioned the exoskeleton of Goniopora and Porites corals are 
made up of calcium carbonate, which biodegrades rapidly. Hydroxyapatite 
is manufactured from these corals by hydrothermal conversion of calcium 
carbonate to calcium phosphate the latter not degradable. It was found that 
biodegradable implants could be manufactured by partial conversion of 
calcium carbonate to hydroxyapatite, limiting the amount of phosphate 
used in the hydrothermal reaction (Klein et al., 1990). Knowing that 
hydroxyapatite implants do induce new bone formation, and knowing that 
the chemical composition of porous hydroxyapatite influences bone 
induction, this study sheds further light on the  initiation of bone induction 
by porous hydroxyapatite in relation to the implants chemical composition 
and the duration of the implant within the animal model. 
 
 
 26
1.4 Aim 
 
 
To study the expression of collagen type II, collagen type IV, BMP-3, BMP-
7, GDF-10, TGF-β1 mRNAs  and the process of new bone formation within 
the vicinity of hydroxyapatite implants, in relation to the type porous 
hydroxyapatite implant used and the implantation period.  
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2   MATERIALS AND METHODS 
 
 
2.1 Porous Hydroxyapatite Implants 
 
The studied hydroxyapatite implants were manufactured by Interpore 
International (Irvine, California). These implants were derived from 
Goniopora, a coral species which secretes a calcium carbonate 
exoskeleton and have an average porosity of 600 µm.  The calcareous 
tissue of the exoskeleton consists of calcium carbonate fibers which can be 
converted to calcium phosphate (hydroxyapatite) by a hydrothermal 
reaction with a phosphate (White & Shors, 1986). 
 
This study employed five different types of porous hydroxyapatite implants:  
100% hydroxyapatite (100% HA) implants, 5% conversion 
hydroxyapatite/calcium carbonate (5% HACC), 13% conversion 
hydroxyapatite/calcium carbonate (13% HACC), sintered hydroxyapatite 
(SHA) and a peptide-coated hydroxyapatite (P15 HA). All implants used 
were rods of 20 mm in length and 7 mm in diameter with an average 
porosity of 600 µm. 
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100% HA implants: 
The 100% HA implants were manufactured by full conversion of calcium 
carbonate to hydroxyapatite. 
 
5% HACC implants:  
When converting the calcium carbonate microstructure in these implants, 
phosphate was limited in the reaction such that only 5% of the calcium 
carbonate was converted to hydroxyapatite.  
 
13% HACC implants: 
While converting a calcium carbonate microstructure in these implants,  
phosphate was limited in the reaction such that only 13% of the calcium 
carbonate was converted to hydroxyapatite 
 
SHA implants: 
The SHA implants were prepared by heating up fully the converted 
hydroxyapatite material to 1100 ºC.  
 
P15 HA implants: 
The P15 HA implants were prepared by coating the fully converted 
hydroxyapatite implants with a synthetic peptide p15, a peptide known to 
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increase the adhesion of fibroblasts to bone mineral (Qian & Bhatnagar, 
1996).  
 
After manufacturing, all the implants were individually packed and sterilised 
using gamma irradiation. 
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2.2 Animal Selection and Care 
 
 Six clinically healthy female Chacma baboons (Papio ursinus), with a 
mean weight of 21.3 ± 3.5 kg were selected from the non-human primate 
colony of the University of the Witwatersrand, Johannesburg. The criteria 
for selection was skeletal maturity, shown radiographically by closure of the 
distal epiphyseal plates of the radius and ulna (Ripamonti, 1991) and 
normal haematological and biochemical profiles (Melton & Melton, 1982).  
Following standard quarantine procedures, the animals were housed 
individually in suspended wire-mesh cages in the non-human primate unit 
of the University of the Witwatersrand, 1800 meters above sea level. The 
rooms of the animals were kept under slight negative pressure (-25 kPa), 
with controlled ventilation (18 filtered air changes each hour), temperature 
kept at 22 ± 2 °C, humidity of 40 ± 10% and the photoperiod of 6 am to 6 
pm. The baboons diet consisted of balanced protein, fat, carbohydrates 
with vitamins (thiamine, riboflavin and nicotinic acid) and mineral 
supplements (calcium: phosphorus = 2:1) and had free access to water. 
The experiment described in this dissertation have been approved and 
cleared by the Animals Ethics Screening Committee of the University of the 
Witwatersrand, Johannesburg (AESC NO. 96/95/5). 
 
 
 31
2.3 Surgical Procedures and Implantation Design 
 
The baboons were starved the evening before surgery, with access to 
water ad libitum. Before surgery, the baboons were immobilised with an 
intramuscular injection of ketamine hydrochloride (8 mg/ kg body weight). 
The baboons were anaesthetised with intravenous sodium thiopentone (15 
mg/ kg weight body weight) and maintained by halothane vapour in 100% 
oxygen after orotracheal intubation. The baboons’ abdomens were then 
shaved and the surgical areas isolated with sterile surgical drapes. Midline 
incisions were made along the abdominal walls, the skins were reflected 
and intramuscular pouches were created bilaterally in the rectus abdominis 
muscles of the baboons. Implants were placed in pouches, with two rods of 
100% HA, two rods of 13% HACC, two rods of 5% HACC, two rods of 
SHA, and only one rod of P15 HA substrata implanted heterotopically in 
each baboon (Figure 2.1). The pouches were then closed by repairing in 
layers the fasciae and the superficial tissues with atraumatic resorbable 
sutures (Vicryl, Ethicon NJ). The animals were then given a mixture of 
benethamine and procaine penicillin intramuscularly. To control pain, they 
were given buprenorphine hydrochloride (0.3 mg) intramuscularly. The 
animals were housed individually and were fed a soft diet until they healed.  
Thereafter they returned to their normal diet as described earlier. All 
animals healed well with no complications. 
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Figure 2-1 Implantation Protocol.  
The implants were fabricated as rods, 20 mm in length and 7 mm in 
diameter. The types of hydroxyapatite implanted in the rectus abdominis 
muscles of the adult baboons were: 
 
            100% hydroxyapatite (100% HA). 
           13% conversion hydroxyapatite (13% HACC). 
            Sintered hydroxyapatite (SHA).  
            5% conversion hydroxyapatite (5% HACC). 
             Peptide-coated hydroxyapatite (P15 HA) (one implant per animal).  
 
   
Right Left 
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2.4 Tissue Harvest 
 
 Anaesthetised animals were killed with an intravenous overdose of sodium 
pentobarbitone on day 60, 90 and 365 post implantation, two animals per 
implantation period. Implants were harvested and subjected to biochemical, 
histological, and molecular analyses (Ripamonti, 1991). The post-operative 
harvesting times were chosen  in order to study molecular mechanisms 
and histological developments within the implants in early stages prior to 
bone formation and during bone formation.   
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2.5 Probes Preparation 
 
2.5.1 Amplification of Eschericia coli Constructs 
 
METHOD: 
The XL1 Blue strain of Escherichia coli (Stratagene) a gift from Professor 
de Wet, University of the Witwatersrand, Johannesburg) was used as a 
vector for transformation and cloning. An overnight culture was prepared in 
Luria Bertani (LB) medium [(0.5 % w/v Bacto-yeast extract; 1 % w/v NaCl; 
Bacto-tryptone (Life Technologies, UK) in deionised water which was 
autoclaved at 121ºC)]. The bacteria were then grown overnight on LB-agar 
plates. To make the bacteria competent, the CaCl2 method was followed 
(Cohen et al., 1972) by picking a single bacterial colony from the LB agar 
plate and inoculating it into 10 ml LB medium containing tube. This was 
incubated overnight at 37°C with vigorous aeration. From this overnight 
incubation 1 ml was taken out and transferred to a sterile 1 litre flask that 
contained 100 ml of LB medium and it was incubated again at 37°C with 
vigorous aeration until the OD600 was approximately 0.4. The cells were 
then transferred to a sterile falcon tube embedded on ice. The cells were 
cooled to 0°C on ice for 10 minutes and were centrifuged at 4000 rpm for 5 
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minutes at 4°C.  The supernatant was discarded and the pellet was 
resuspended in 10 ml of ice-cold 0.1 M CaCl2 and stored on ice for 30 
minutes. The cells were centrifuged again at 4000 rpm for 5 minutes at 
4°C. The pellet was resuspended on 2 ml ice-cold 0.1 M CaCl2  for each 50 
ml of the original culture, then mixed with glycerol (0.15 ml glycerol: 0.85 ml 
cells) and stored at -70 ºC prior to  use. 
 
2.5.2 Transformation of Eschericia  coli. 
 
PROBES USED: 
The following probes were used: 
 
Type II collagen cDNA:  a 2.2 kb fragment of the gene coding for amino 
acids 343 of the triple helix to 70 amino acids inside the C-propeptide 
(Baldwin et al., 1989) cloned into AR5960. 
 
Type IV Collagen-alpha cDNA: the most collagenous domain (Hostikka & 
Tryggvason., 1988) cloned into Ac2.  
 
BMP-7 cDNA: comprises of 679 bp cloned in p0320  and encodes amino 
acids 63 to 262 of the pro-region and the first 25 amino acids of the mature 
polypeptide (Özkaynak et al., 1990) 
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TGF-β1 cDNA: the unmodified wild type of the TGF-β1 precursor cloned 
into pRK5 (Derynck et al., 1985).  
 
BMP-3 cDNA: has 1508 bp EcoRI fragment insert including the full coding 
region of hBMP-3 (Wozney et al., 1988).  
 
GDF-10 cDNA : cloned into p5k  (Cunningham et al., 1995)  
 
Gamma actin cDNA 
 
cDNAs for gamma-actin, collagen type II and collagen type IV were gifts 
from Professor de Wet, University of the Witwatersrand, Johannesburg. 
 
cDNAs for BMP-7 and TGF-β1 were gifts from Professor Vukicevic, 
University of Zagreb, Croatia. 
 
The cDNAs for BMP-3 and cDNAs for GDF-10 were gifts from Professor A. 
Hari Reddi, John Hopkins Maryland, USA. 
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METHOD: 
For transformation, 200 µl of Eschericia coli bacterial suspension was 
transferred to a sterile polypropylene tube. Super coiled plasmid DNA (100 
ng) was added to the tube, mixed and stored on ice for 30 minutes. A 
control was made with competent bacteria that received no plasmid. The 
cells were then transferred to a water bath at 42ºC for 90 seconds, and 
back on ice for 2 minutes. LB medium (800 µl) was added to the cells and 
with gentle aeration they were incubated at 37°C for 45 minutes, allowing 
the bacteria to express the antibiotic resistance markers encoded by the 
plasmid DNAs. 100 µl of transformed competent cells were plated onto LB 
agar plates which contained an antibiotic. The cells were then inverted and 
incubated at 37°C overnight.  
 
 
2.5.3 Preparation of Plasmid DNA  
 
A High Pure Plasmid kit Isolation Reagent, (Boehringer Mannheim) was 
used for this purpose. Plasmid DNA was isolated from E.coli (XL1 Blue) by 
lysing the bacterial cells according to the alkaline lysis method (Birnboim 
and Dolly, 1979). An overnight culture of transformed bacterial cells was 
grown in 4 ml of LB at 37oC. Cells were collected by centrifugation at 
4300g for 5 minutes in a GS3 rotor. The cells were lysed and bacterial RNA 
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was removed by the addition of RNAse A supplied with the kit. The lysate 
was neutralised and adjusted to high salt binding conditions after which 
chromosomal DNA was precipitated and the supernatant, which contained 
the plasmid was purified from the salts, proteins and other cellular 
impurities in 10 mM Tris-HCl buffer. 
 
 
2.5.4 Preparation of Probe Labeled with α-32P  
 
METHOD: 
 The vector DNA was cleaved using restriction enzymes. Restriction 
digests of plasmid vectors and molecular weight markers were separated 
by electrophoresis through 1% (w/v) agarose gel in 1X Tris borate (TBE) 
buffer at 5 V/cm. The DNA was visualised by staining with ethidium 
bromide and viewing on a UV transilluminator. The concentration of DNA 
was determined by the spectrophotometric analysis: an absorbance 
reading of 1 unit at 260 nm corresponds to a DNA concentration of 50 
µg/ml. 
 
DNA, 25 ng, was labeled with α-32P dCTP using a random prime labeling 
kit (DNA Megaprime labeling kit RPN 1606, Amersham Life Science, UK).  
The DNA purification kit (QIA quick, QIAGEN Germany, supplied by White 
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Head Scientific South Africa) was used to remove unincorporated label and 
the purified probe was used for hybridisation. 
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2.6 Northern Blot Analysis 
 
2.6.1 Preparation of mRNA 
 
METHOD: 
Total RNA was extracted from pooled tissues of replicate 100 mg 
specimens. All glassware was baked at 250ºC over night and plastic ware 
autoclaved at 121ºC for 20 minutes. All solutions were prepared with 
deionised water treated with 0.1% DEPC (ICN Biochemicals Inc. Ohio). 
The harvested samples which were stored at -70ºC were crushed to fine 
powder with sterilised utensils pre-cooled at -70ºC. TriPure™ Isolation 
Reagent (Boehringer Mannheim Biochemicals, Germany) was added to the 
crushed samples and homogenised with an IKA Ultra-Turrax T025 (Janke 
and Kunkel, Staifen, Germany) tissue homogeniser at 20000 rpm, the 
samples were then centrifuged at 4300g for 10 minutes at 4ºC in a GS3 
rotor. The supernatants were aliquoted in microcentrifuge tubes. 0.2 ml of 
chloroform was added and the tubes were shaken to allow mixture of the 
contents, and then incubated at room temperature for 15 minutes. This 
procedure was followed by centrifugation of the samples at 4300g at 4°C 
for 20 minutes in a GS3 rotor to separate the protein and RNA phases. The 
upper layer that contained RNA was transferred to new microcentrifuge 
tubes and 0.5 ml of 100 % isopropanol was added to 1 ml of RNA layer. 
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Following incubation at room temperature for 15 minutes, the samples 
were centrifuged again at 4300g at 4°C for 20 minutes in a GS3 rotor to 
pellet the RNA. The supernatant was discarded and the RNA pellet washed 
with cold 75% ethanol to reduce salt concentration.  The ethanol was 
discarded after 15 minutes using a small-tipped pipette and the RNA 
pellets were air dried for about 10 minutes.  The RNA pellets were 
resuspended in 20 µl of 1X resuspension buffer (0.5% lauryl sarcosine, 
5mM EDTA, pH 8.0). RNA concentration was determined 
spectrophotometrically at 260 nm by using an extinction coefficient of 1 
representing a concentration of 40 µg/ml. The quality of the RNA was 
judged by the A 260 /A280 ratio of absorbance of the samples, visualization of 
the RNA bands on agarose gels and by the quality of gamma actin signals 
on the Northern blots. 
 
 
2.6.2 Formaldehyde Agarose Gel Electrophoresis 
 
GEL PREPARATION: 
A 1.2% (w/v) agarose gel was prepared by mixing agarose powder with 
0.1% DEPC-treated water.  The solution was heated up to allow 
homogenization. Concentrated electrophoresis buffer (0.1M MOPS, 40 mM 
Sodium Acetate, 5 mM EDTA) was added to this solution. Formaldehyde 
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was added when the solution had cooled down making the final gel 
concentration of 1.2% (w/v) agarose. The contents were poured onto gel 
trays and allowed to set for at least 45 minutes at room temperature prior to 
electrophoresis. 
 
ELECTROPHORESIS: 
Preceding electrophoresis, samples of RNA were denatured at 65°C in 
formamide, formaldehyde and 5 X electrophoresis buffer (0.1M MOPS, 40 
mM Sodium Acetate, 5 mM EDTA). Samples were mixed with the gel 
loading buffer and loaded in the wells of the agarose gel. The 5 X 
electrophoresis buffer was poured onto gel trays submerging electrodes 
and the gel, electrophoresis was carried out at 5 V/cm. After 
electrophoresis the gel was stained with ethidium bromide (Boehringer 
Mannheim Biochemicals) 0.5 µg/ml in 0.1 sodium acetate for 1hour then 
de-stained overnight with three changes of DEPC treated water. The gel 
was placed on an UV transilluminator to visually assess the RNA quality.  
 
2.6.3 Transfer  of RNA 
 
RNA TRANSFER PROCEDURE: 
RNA was transferred to a nylon membrane (Hybond N+, Amersham, UK) 
by capillary blotting using Semi-Dry transfer Cell (Biorad) apparatus 
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specific for Northern blot analysis  (Life Science Technologies, UK). The 
transfer was allowed to proceed for overnight in the presence of 20X SSC 
(175.3 g Sodium Chloride, 88.2 g   Tri-Sodium Citrate, in 1litre of milli Q 
water treated with 0.1  %  diethylpyrocarbonate (DEPC) ) (Saambrook et 
al., 1989). The membrane was baked at 80ºC to effect the crosslinking of 
RNA to the nylon membrane. 
 
2.6.4 Hybridisation  
 
PRE-HYBRIDISATION AND HYBRIDISATION: 
The membranes were prehybridised by immersion into a hybridisation 
solution (QuickHYB, White Head Scientific) and placed inside the 
hybridisation oven (Hybridisation oven, Hybaid Corporation, UK) set at 
68°C for 40 minutes. In the mean time probes were mixed with sonicated 
fish sperm DNA (10 mg/ml) and boiled for two minutes to denature the 
DNA. Then prehybridised membranes, together with the probes were put in 
50 ml falcon tubes, with a mesh between the tube and the membrane. 
Hybridisation was allowed to proceed for two hours in the hybridisation 
oven at 68°C.  The membranes were washed twice for 15 minutes at room 
temperature with 150 ml of 2 X SSC, 0.1 % SDS  followed by the 
stringency wash at 68°C with 0.1 X SSC, 0.1% SDS. The membranes were 
dried on the blotting paper and covered with a Saran wrap. The hybridised 
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membranes were exposed to Kodak film (Biomax MS) with intensified 
screens 15 to 75 hours at -70˚C. Signals were quantified relative to gamma 
actin blots by densitometric analysis (Gel documentation and Analysis 
system, Syngene, U.K) (Matsaba et al., 2001). 
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2.7 Histology 
 
Harvested tissues were fixed in 10% phosphate buffered formaldehyde (pH 
7.4) and demineralised in formic acid-hydrochloric acid solution (Molnar, 
1975). The end of decalcification was marked by the absence of a 
precipitate when 1ml of ammonium oxalate was added to 5ml of the 
decalcifying solution. Decalcified specimens were processed using a 
celloidin paraffin wax double embedding procedure (Bancroft & Stevens, 
1996). Specimen blocks were sectioned on a Microm HM360 (Microm 
Laborgerate GmbH, Walldorf, Germany) rotary microtome with a section 
transfer system. Serial sections cut at 5µm were picked up onto 
formaldehyde/gelatin coated glass slides to minimise section detachment 
during staining. Sections were stained using a modified Goldner's Trichome 
method outlined below (Ripamonti et al., 1997; Duneas et al., 1998; 
Ripamonti et al., 1999; Ripamonti et al., 2000). Sections were analysed in 
an Olympus Provis AX70 research light microscope (Olympus, Tokyo, 
Japan) at a 10X magnification. 
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2.7.1 Method (Modified Goldner’s Trichome) 
 
Sections were stained in stable iron haematoxylin for 20 minutes, Fuschin 
Ponceau for 45 minutes, differentiated in Orange G for 20 minutes then 
stained in methyl blue for 10 minutes. In between the stains, sections were 
washed in running tap water, differentiated in acid alcohol and immersed in 
1% acetic acid. The sections were then dehydrated in series of alcohol and 
mounted with entellan (Merck, Germany). 
 
The difference between the original Goldner’s stain and the modified 
method is the counterstaing. The original method counterstains with a 
green stain while the modified method counterstains with a blue stain so 
everything that is green representing mineralized bone in the original 
method will appear blue in the modified method. The blue stain 
representing mineralised bone was chosen for photographic purposes. 
Bone is differentiated from the dense connective tissue and any other 
tissue that make the blue stain by the fact that bone has osteocytes; this is 
a characteristic feature that all the other tissues in the study do not have. 
Morphologically, bone stains blue on decalcified sections (with modified 
Goldner’s Trichome) as matrix filled with osteocytes and osteoblastic cells 
is often highly vascularised. 
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2.7.2 Histomorphometric Analysis 
 
Specimen sections were subjected to histomorphometric analysis as 
described by Ripamonti (1991). A square Zeiss Intergration Plate II (Zeiss, 
Orberkochen,Germany) with 100 lattice points and a total area of 7.84 mm2 
was used to calculate the volume fraction composition of tissue 
components with the point counting technique (Parfitt, 1983). The 
technique computes fraction volumes in percent of histological components 
including bone, soft tissue and the hydroxyapatite substratum.  
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2.8 Statistical Analysis 
 
The data were analysed using the GraphPad Prism ™ Version 2.0 
(GraphPad Software Inc, San Diego, CA).  A two-way analysis of variances 
test was used to determine the differences in expression of selected genes 
in respect to time and type of porous hydroxyapatite used. The level of 
significance used was p< 0.05. 
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3  RESULTS 
 
 Unlike Collagen type IV, BMP-7 and GDF-10 mRNAs, It was found that  
Collagen type II, BMP-3 and TGF-β1 mRNAs were not expressed at 
detectable levels in all the samples at all time periods. The intensity of the 
expression of Collagen type IV mRNA, BMP-7 mRNA and GDF-10 mRNA 
were normalized as percentages against gamma-actin intensity levels (in 
Densitometric Units), the Relative Densitometric Units (RDU) of these 
mRNAs in all implants were as follows: 
 
Collagen Type IV mRNA expression 
There was similarity in expression patterns of Collagen type IV mRNA  
(Appendix A) in all five types of hydroxyapatite implants. At two months 
Collagen type IV was highly expressed in all of the hydroxyapatite implants: 
range 0.74 to 0.98 relative densitometric units (RDU) (Figure 3-1). These 
expression levels decreased at three months (range 0.32 – 0.94 RDU). The 
levels of Collagen type IV mRNA at three months in P15 HA were lower 
than the levels detected in other implants. However, this difference was not 
statistically significant.  There was a further statistically significant  
reduction in Collagen type IV expression at 12 months in all the implants  
(ranging from 0.05-0.20 RDU). 
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BMP-7 mRNA expression 
All of the five different types of hydroxyapatite studied showed relatively 
high expression levels of BMP-7 mRNA at two months (range 0.94-0.99 
RDU) (Figure 3-2) . These expression levels decreased at three months 
(range 0.14-0.36 RDU) and at 12 months there was a further reduction of 
BMP-7 mRNA levels (range 0.06-0.12 RDU) (Appendix B). 
  
GDF-10 mRNA expression 
The levels of GDF-10 mRNA at two months (range 0.17- 0.3 RDU) were 
low relative to the mRNA levels of Collagen type IV and BMP-7 at two 
months (Figure 3-3; compare Figures 3-1 and 3-2). The levels of GDF-10 
mRNA (Appendix C) decreased at three months (range 0.04- 0.18 RDU) 
(Figure 3-3)  and were decreased even more at 12 months (range 0-0.12 
RDU). The SHA expressed no detectable GDF-10 mRNA at 12 months. It 
was surprising to find that the GDF-10 mRNA levels at 12 months in 13% 
HACC implants were higher than expression levels at three months. 
However, the GDF-10 message was lower at three months than at two 
months showing a fluctuating pattern. However, there was no significant 
difference in the expression of GDF-10 mRNA between all studied 
implants. 
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The ANOVA test indicates that there is no significant difference in the 
variability of the levels of mRNA (Collagen type IV, BMP-7 and GDF-10) 
expressed in the five different types of hydroxyapatite implants studied (p < 
0.05). A significant difference was found in the level of mRNA expressed 
and the duration of sample implantation (p<< 0.01). The mRNA expression 
levels generally decreased with time. 
 
Histology 
The decalcified sections shown from Figure 3-4 to Figure 3-8 illustrating 
that at two months (A) there was invasion of dense, highly vascularised 
connective tissue within the porous spaces of the hydroxyapatite implants, 
with fibrous connective tissue aligned at the hydroxyapatite interface. At 
three months (B) the figures show that there was a loose cellular 
connective tissue which was highly vascularised with denser fibres at the 
implant interface. Most importantly there was no new bone formed at two 
and three months in all five types of porous hydroxyapatite implants. 
 
The results of the specimen harvested at 12 months are shown in panel C 
in figures 3-4 through to figure 3-8. These specimens showed substantial 
amounts of new bone formed (indicated by arrows in figures) within all 
types of porous hydroxyapatite used. The new bone was formed 
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peripherally, at the hydroxyapatite implant interface as profoundly shown in 
figure 3-6 (c). 
 
 
 
Histomorphometry 
Histomorphometric results of the specimen are summarized in Table 3-1 
(Crooks, 2001). The results showed that at two and three months there 
was no bone in all implants and no significant difference between the 
implants. Substantial amount of bone was formed at 12 months. There was 
no significant difference in the amount of bone formed between the 
different implants that were studied.  
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Figure 3-1 Photomicrographs of various stages of bone 
induction within fully converted hydroxyapatite (100 % HA) 
implants.  
The 5 µm thick decalcified sections were stained with modified Goldner’s 
Trichome (x10 magnification). (A and B) are sections from implants 
harvested at two and three months respectively, showing blood vessels 
(bent open arrows). (C) Sections from implants harvested at 12 months, 
mineralised bone is stained blue (arrows).   
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Figure 3-2 Photomicrographs of various stages of bone 
induction within partially converted (5 % HA) implants.  
The 5 µm thick decalcified sections were stained with modified Goldner’s 
Trichome (x 10 magnifications). (A and B) are sections from implants 
harvested at two and three months respectively, showing blood vessels 
(bent open arrows). (C) Sections from implants harvested at 12 months, 
mineralised bone is stained blue (arrows).  
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Figure 3-3 Photomicrographs of various stages of bone 
induction within partially converted 13 % HACC implants.  
The 5 µm thick decalcified sections were stained with modified Goldner’s 
Trichome (x 10 magnifications). (A and B) are sections from implants 
harvested at two and three months respectively, showing blood vessels 
(bent open arrows). (C) Sections from implants harvested at 12 months, 
mineralised bone is stained blue (arrows). 
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Figure 3-4 Photomicrographs of various stages of bone 
induction within sintered hydroxyapatite (SHA) implants.  
The 5 µm thick decalcified sections were stained with modified Goldner’s 
Trichome (x 10 magnifications). (A and B) are sections from implants 
harvested at two and three months respectively, showing blood vessels 
(bent open arrows). (C) Sections from implants harvested at 12 months, 
mineralised bone is stained blue (arrows).  
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Figure 3-5 Photomicrographs of various stages of bone 
induction within hydroxyapatite implants coated with p-15 
(P15 HA).  
The 5 µm thick decalcified sections were stained with modified Goldner’s 
Trichome (x 10 magnifications). (A and B) are sections from implants 
harvested at two and three months respectively, showing blood vessels 
(bent open arrows). (C) Sections from implants harvested at 12 months, 
mineralised bone is stained blue (arrows). 
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Table 3-1 Volume fraction composition (%) of decalcified 
heterotopic specimens of types of hydroxyapatite harvested 
at two, three and 12 months. 
 
Treatment               Bone     Fibrovascular          Substratum 
                                                        Tissue 
 
2 months 
100% HA      0.88                 65.63 ± 1.10            36.50 ± 1.21 
SHA                 0.00                 68.25 ± 1.53                 33.75 ± 1.54 
5% HACC            0.00                 69.25 ± 1.87                 27.50 ± 0.95 
13% HACC      0.00                 62.75 ± 3.03                 31.25 ± 0.86  
P15  HA                       0.00                 68.00 ± 2.15                 29.00 ± 1.79 
 
3 months 
100% HA                      0.00                 64.63 ± 2.16                 35.38 ± 2.16 
SHA                              0.00                 70.50 ± 1.35                 29.50 ± 1.35 
5% HACC                     0.00                 69.25 ± 2.11                 30.75 ± 2.11 
13% HACC                   0.00                 64.13 ± 1.36                 35.87 ± 1.36  
P15 HA                         0.00                 63.25 ± 1.47                 36.75 ± 1.47 
 
12 months 
100% HA                      23.50 ± 4.29     43.00 ± 2.17                 33.50 ± 2.31 
SHA                              17.75 ± 6.82     48.75 ± 5.82                 33.50 ± 2.00                       
5% HACC                     8.88 ± 3.55       51.75 ± 4.58                 31.25 ± 6.04 
13% HACC                   25.13 ± 2.41     42.37 ± 3.17                 32.50 ± 2.92 
P15 HA                         29.50 ± 1.54     43.38 ± 2.11                 27.13 ± 1.74 
 
 
Volume fractions of tissue components were calculated using Zeiss 
Intergrated Platte II with 100 lattice points superimposed over 4 sections 
per specimen. Substratum indicates the implanted framework of types of 
hydroxyapatite, having n=4 for all the substratum except p15 HA where 
n=2. Values (in percentage) are means ± standard error of the mean 
(Crooks, 2001). 
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4 DISCUSSION 
 
To shed further light on the molecular signals that trigger intrinsic 
osteoinduction by heterotopically implanted porous hydroxyapatite (HA), 
the expression of osteogenic markers was studied. Different types of HA 
were implanted in the rectus abdominis muscles of the baboons and 
harvested at different time periods. To relate the different expression 
patterns of the osteogenic markers and morphological changes within the 
implants histological sections of the specimens were also studied. 
 
Collagen type IV is a major constituent of vascular basement membranes. 
Previous studies have shown that one of the prominent features of 
osteoinduction at one and two months is the angiogenic response 
surrounding and penetrating the porous hydroxyapatite substrata 
(Ripamonti et al., 1993). The study of laminin and collagen type IV during 
angiogenesis in endochondral bone formation indicates that there is a 
close relationship between vascular invasion and subsequent bone 
formation (Foidart & Reddi, 1980). Trueta (1963) has shown that 
angiogenesis and vascular invasion are prerequisites for osteogenesis, 
since blood supply is important for delivery of oxygen, nutrients and bone 
forming morphogens to the induction site (Reddi, 2000; Geber & Ferrare, 
2000; Colnot & Helms, 2001). The high expression of collagen type IV 
message, a marker of angiogenesis (Foidart & Reddi, 1980; Ramoshebi & 
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Ripamonti et al., 2000) at two and three months in this study suggests high 
angiogenic response, these results corresponds with histology showing 
blood vessels within the porous spaces of HA implants. The down 
regulation of Collagen type IV message at 12 months corresponds with 
maximum bone formation, suggesting a biofeedback mechanism that 
regulates the amount of blood vessels formed during osteogenesis. 
 
There was no detectable expression of Collagen type II message, a marker 
of chondrogenic phenotype. This is consistent with the observation that 
bone formation occurring in porous hydroxyapatite implants does not 
proceed via chondrogenic phase (Ripamonti, 1991; Ripamonti et al.,1999; 
2000;and the histological results in this study), possibly because of the 
implants geometry which allow rapid vascularisation that occurs at early 
stages of bone formation (Ripamonti et al., 1999). Cartilage is an avascular 
tissue and vascularisation marks the onset of its degradation (Trueta, 
1963). The histological results in this study show that from as early as two 
months there was substantial vascularisation, and no chondrogenic phase 
as cartilage is avascular.  
 
The expression of BMP-7 mRNA in all HA types were high at two months, 
dropping by three months and further reduced at 12 months. The 
osteoinductive properties of BMP-7 have been observed in several 
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experiments. It has been reported that implantation of recombinant BMP-7 
along the lamina and facets of canines induced a solid interlaminar fusions 
by 12 weeks, as compared to 22 weeks when using autologous bone grafts 
(Cook et al., 1994).  Implantation of high doses of BMP-7 in calvarial 
defects in another study induced massive bone differentiation at day 30 
(Ripamonti & Reddi, 1994), showing the importance of BMP-7 in new bone 
formation and how exogenous application of BMP-7 within implants 
accelerates new bone formation.  BMP-7 also has angiogenic properties 
(Ramoshebi & Ripamonti, 2000). Supporting this statement are ossicles 
which when induced with BMP-7 and TGF-β1 expressed several fold 
increase in type IV Collagen mRNA expression, showing a synergistic 
interaction of TGF-β1 and BMP-7 to induce vascular invasion (Duneas et 
al., 1998). In the present study expression of BMP-7 message in the cells 
invading the implants shows that in early stages it is highly expressed and 
its expression fades with time. The expression of BMP-7 message is critical 
in angiogenesis and osteoinduction mechanism and it is important that 
these mechanisms are regulated temporally. 
 
The BMP-3 transcripts were not expressed in the cells invading the porous 
spaces of hydroxyapatite substrata, suggesting adsorption of the protein 
from the circulatory system.  Previous studies conducted on BMP-3 shows 
that this morphogen has high affinity for Collagen type IV (Paralkar et al., 
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1990). Also, adsorption of BMP-3 onto hydroxyapatite resulted in 
osteogenesis within porous spaces of the substrata when implanted 
heterotopically in rodents (Ripamonti et al., 1992b). When purified BMP-3 
was adsorbed to porous hydroxyapatite and implanted orthotopically in 
baboons, extensive bone induction was reported (Ripamonti et al., 1992c).    
The absence of BMP-3 mRNA expression in the present results can be 
explained by the possibility that BMP-3 are not being locally expressed but 
binding to the implants from the circulation.  
 
The GDF-10 transcripts in this study were expressed at low levels 
compared to expression of BMP-7 and Collagen type IV transcripts (figure 
3-3). Even though the GDF-10 mRNA transcript levels were low at two 
months there was still a further decrease observed at three months and 
even a greater decrease at 12 months indicating that it is temporally 
regulated. However in 13% HACC implants at 12 months, the GDF-10 
transcription level was higher than that detected at three months but lower 
than the GDF-10 transcription level at two months. As this rise at 12 
months was not detected in other studied implants, it is suspected that 
these fluctuating transcription levels are related to the type of implant used, 
perhaps a longer study would show significant difference in the amount of 
bone formed between the other  HA implants and 13% HACC. The 
fluctuating transcription levels may also be related to other growth factors 
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that are expressed within the 13% HACC implant or adsorbed to this 
particular substratum. 
  
GDF-10 was found to be closely related to BMP-3, and strongly expressed 
in both neonatal and adult flat bones, with lower levels detected in bones of 
endochondral origin such as the femur (Cunningham et al., 1995). A recent 
study showed that although GDF-10 transcripts were expressed in ossicles 
with chondrogenic phase, its expression was greater in ossicles in which 
osteogenesis was not via chondrogenic phase but was intramembranous 
(Ripamonti et al., 2000). In the present study, osteogenesis in all five 
different types of porous implants was intramembraneous and thus the 
expression of GDF-10 clearly seen. Temporal regulation of GDF-10 is also 
demonstrated in this study. 
 
TGF-β1 transcripts were not detected in the studied porous substrata. 
TGF-β1 protein is known to have high affinity to collagen type IV (Paralkar 
et al., 1991).  In previous studies, TGF-β1 induced endochondral bone 
formation when implanted extraskeletally in baboons (Ripamonti et al., 
1997; Duneas et al., 1998). Endochondral bone formation could also be 
accelerated by binary application of TGF-β1 with BMP-7 heterotopically 
and orthotopically in baboons (Duneas et al., 1998). The lack of TGF-β1 
expression in the cells that invade the porous spaces of the implants does 
 72
not dismiss the evidence that TGF-β1 plays a major role in osteogenesis. 
However, the lack of detection of TGF-β1 message expression suggests 
that it is not locally expressed but may bind to the implant from the 
circulation, considering the affinity of TGF-β1 to collagen type IV. 
 
There was a high inverse correlation between the levels of mRNA 
expressed and time of harvest. It is possible that the decrease in mRNA 
transcripts of BMP-7, collagen type IV and GDF-10 as the time period 
increases is caused by synthesis of the protein these transcripts encodes. 
As more protein is synthesised to initiate bone formation as seen in 
histological sections there could be a negative feedback mechanism that 
inhibits production of more mRNA transcripts. Another possibility could be 
the activation of the morphogens inhibitors such as Smads, in response to 
the synthesised proteins and new bone formed. This could also be 
triggered by progression of osteogenesis into marrow formation.  
 
The histological  results of these specimens (Figure 3-4, Figure 3-5, Figure 
3-6, Figure 3-7, Figure 3-8 ) indicates that at two and three months there 
was no bone formed in all the implants. However, at 12 months there was 
substantial bone formed in all forms of hydroxyapatite implants studied 
(Table 3-1). These histological results support the lack of difference in the 
expression of osteogenic markers between substrata, and also support the 
 73
significant difference that the period of implantation makes in the 
expression of these markers. It is also interesting that the expression of the 
osteogenic markers within the implants is reduced with time, suggesting 
that new bone will not grow ad infinitum but will be regulated with time. It 
should be noted that this study employed only a small number of 
specimens which could affect statistical interpretation of the results. 
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5 CONCLUSION 
 
The results of this study show that the expression of Collagen type IV, 
BMP-7 and GDF-10 mRNAs are temporally regulated in all osteoinductive 
hydroxyapatite implants, having the highest expression at two months and 
the lowest expression levels at 12 months when there is substantial 
amount of bone formed within the implants. This temporal regulation may 
be in response to the amount of bone formed within the implants, triggering 
some negative feedback mechanism which works through inhibitory Smads 
proteins so as to control the amount of new bone to be formed. It is 
possible that osteogenic markers BMP-3 and TGF-β1 were not expressed 
within the implanted HA but that proteins are recruited and bind to the 
porous HA from the circulatory system.  Further analysis such as western 
blot technique are needed to shed further light on the molecular 
mechanisms involved in the intrinsic osteoinductive properties of the 
porous hydroxyapatite implants.  
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6 APPENDIX A 
 
Table A. Mean Values and Standard Deviations from 
normalized Relative Densitometric Units of Collagen type IV 
signal levels expressed within different types of 
hydroxyapatite harvested at different periods.  
 
 
Type of 
implant 
 2 Months 3 Months 12 Months 
Mean 98.025 84.800 24.150 
SD 8.108 18.780 3.515 
 
100% HA 
N 4 4 4 
 
Mean 84.350 70.300 20.350 
SD 2.914 12.465 1.136 
 
13% HACC 
N 4 4 4 
 
Mean 82.950 74.825 9.550 
SD 3.511 4.421 3.979 
 
SH 
N 4 4 4 
 
Mean 74.125 32.800 5.400 
SD 3.966 13.965 3.405 
 
5% HACC 
N 4 4 4 
 
Mean 74.300 32.000 18.150 
SD 0.141 1.414 1.626 
 
P15-HA 
N 2 2 2 
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7 APPENDIX B 
 
Table B. Mean Values and Standard Deviations from 
normalized Relative Densitometric Units of BMP-7 signal 
levels expressed within different types of hydroxyapatite 
harvested at different periods  
 
 
Type of 
implant 
 2 Months 3 Months 12 Months 
Mean 94.500 14.750 11.725 
SD 6.758 7.095 4.903 
 
100% HA 
N 4 4 4 
 
Mean 97.850 21.150 6.900 
SD 9.774 4.122 1.378 
 
13% HACC 
N 4 4 4 
 
Mean 96.500 36.650 9.000 
SD 5.745 12.891 7.703 
 
SH 
N 4 4 4 
 
Mean 99.375 34.700 12.825 
SD 9.446 15.200 1.558 
 
5% HACC 
N 4 4 4 
 
Mean 95.150 36.800 11.050 
SD 11.452 16.380 2.557 
 
P15-HA 
N 2 2 2 
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8 APPENDIX C 
 
Table C. Mean Values and Standard Deviations from 
normalized Relative Densitometric Units of GDF-10 signal 
levels expressed within different types of hydroxyapatite 
harvested at different periods.  
 
 
Type of 
implant 
 2 Months 3 Months 12 Months 
Mean 23.425 12.850 10.750 
SD 2.741 1.134 1.210 
 
100% HA 
N 4 4 4 
 
Mean 17.250 4.875 12.250 
SD 2.646 1.625 3.500 
 
13% HACC 
N 4 4 4 
 
Mean 28.975 10.550 0.025 
SD 1.401 2.822 0.009 
 
SH 
N 4 4 4 
 
Mean 24.475 15.150 8.000 
SD 4.818 1.617 1.826 
 
5% HACC 
N 4 4 4 
 
Mean 30.700 18.200 11.250 
SD 0.990 1.697 3.182 
 
P15-HA 
N 2 2 2 
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